Biomed Industries, Inc. to Acquire MedAware Systems, Inc. to Expand Its Artificial Intelligence Research for Drug Discovery in Alzheimer’s Disease
Summary
He continued, “Our massive data set on dementia, culled from over 3,000 clinical trials as well as over 7,000 published papers on the topic will empower deep analysis of the state-of-the-art in the field and to focus our considerable AI and machine learning capabilities to rapidly accelerate new drug development. We will also expand our current work with pharmaceutical and medical device companies under the aegis of a much larger organization to accelerate market penetration and revenue growth.”The Board of Directors of MedAware having approved this Agreement, has scheduled a shareholder meeting to vote on the Share Exchange Agreement and Plan of Reorganization on or before September 28, 2022.Approval for the Transaction will be sought from BIOMED’s shareholders at a special meeting of shareholders currently scheduled for September 30, 2022, which will be held electronically.About Biomed Industries, Inc.Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs. Biomed is a leading innovator, having discovered a new family of drugs which are in the clinical stage for the treatment of Alzheimer’s disease. Combining Real World Evidence (RWE) extracted from government adverse event databases and social media with scientific data from published medical research (meta-analysis), the Company provides unprecedented business intelligence to support regulatory filings, competitive analysis, and marketing messaging. For more information, please visit https://medawaresystems.com.For media enquiries, please contact:Biomed Industries, Inc.San Jose, CA 95131 USATel.